Estelle Tran Van Hoi, Stella Trompet, Yara Van Holstein, Frederiek Van Den Bos, Diana Van Heemst, Henrik Codrington, Geert Labots, Suzanne Lohman, Asli Ozkan, Johanneke Portielje, Simon P Mooijaart, Nienke A De Glas, Marloes Derks
BACKGROUND: Checkpoint inhibition has emerged as an effective treatment strategy for a variety of cancers, including in older adults. However, older patients with cancer represent a heterogenous group as they can vary widely in frailty, cognition, and physical status. OBJECTIVE: This study aims to investigate the association between clinical frailty and immune-related treatment toxicity, hospitalization, and treatment discontinuation due to immune-related treatment toxicity in older patients treated with checkpoint inhibitors...
May 10, 2024: Drugs & Aging